Cargando…

Cancer testis antigen expression in triple negative breast cancer: Candidate targets for cancer immunotherapy?

Detalles Bibliográficos
Autores principales:	Hendrickx, Wouter, Al-Muftah, Mariam, Decock, Julie
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2015
Materias:	Poster Presentation
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4649287/ http://dx.doi.org/10.1186/2051-1426-3-S2-P381

Ejemplares similares

Cancer testis antigen PRAME: An anti‐cancer target with immunomodulatory potential
por: Naik, Adviti, et al.
Publicado: (2021)

Cancer Testis Antigens and Immunotherapy: Where Do We Stand in the Targeting of PRAME?
por: Al-Khadairi, Ghaneya, et al.
Publicado: (2019)

Cancer testis antigen Sperm Protein 17 as a new target for triple negative breast cancer immunotherapy
por: Mirandola, Leonardo, et al.
Publicado: (2017)

The Obesity Paradox in Cancer, Tumor Immunology, and Immunotherapy: Potential Therapeutic Implications in Triple Negative Breast Cancer
por: Naik, Adviti, et al.
Publicado: (2019)

Oncogenic cancer/testis antigens: prime candidates for immunotherapy
por: Gjerstorff, Morten F., et al.
Publicado: (2015)

Inducible expression of antigen processing and antigen presentation molecules and cancer testis antigens in human prostate cancer
por: Heninger, Erika, et al.
Publicado: (2015)

Tissue factor-targeted immunotherapy of melanoma and triple negative breast cancer using a second generation ICON
por: Hu, Zhiwei, et al.
Publicado: (2015)

Clinical features and prognosis of triple-negative breast cancer
por: Sanz, M Izquierdo, et al.
Publicado: (2009)

Cancer Testis Antigen Promotes Triple Negative Breast Cancer Metastasis and is Traceable in the Circulating Extracellular Vesicles
por: Kannan, Anbarasu, et al.
Publicado: (2019)

Plasma MMP1, MMP8 and MMP13 expression in breast cancer: protective role of MMP8 against lymph node metastasis
por: Decock, J, et al.
Publicado: (2008)

Editorial: Cancer testis antigens in cancer: Recent developments as cancer biomarkers and therapeutic targets
por: Naik, Adviti, et al.
Publicado: (2022)

The MAPK hypothesis: immune-regulatory effects of MAPK-pathway genetic dysregulations and implications for breast cancer immunotherapy
por: Bedognetti, Davide, et al.
Publicado: (2017)

In silico design of a triple-negative breast cancer vaccine by targeting cancer testis antigens
por: Parvizpour, Sepideh, et al.
Publicado: (2019)

Cancer-Testis Antigens in Triple-Negative Breast Cancer: Role and Potential Utility in Clinical Practice
por: Lam, Runyi Adeline, et al.
Publicado: (2021)

Cancer testis antigen and immunotherapy
por: Krishnadas, Deepa Kolaseri, et al.
Publicado: (2013)

Association of MMP8 gene variation with breast cancer prognosis
por: Decock, J, et al.
Publicado: (2008)

Expression of cancer testis antigens and its correlation with clinicopathological parameters in hepatocellular carcinoma
por: Wang, Meng, et al.
Publicado: (2013)

Expression of cancer-testis antigen in patients with non-small cell lung cancer and its clinical relevance
por: Chen, Xin-Feng, et al.
Publicado: (2013)

NY-ESO-1 Cancer Testis Antigen Demonstrates High Immunogenicity in Triple Negative Breast Cancer
por: Ademuyiwa, Foluso O., et al.
Publicado: (2012)

In vitro antineoplastic activity in triple-negative breast cancer cell line and in vivo
por: Madeira, Klesia, et al.
Publicado: (2014)

Author Correction: Cancer Testis Antigen Promotes Triple Negative Breast Cancer Metastasis and is Traceable in the Circulating Extracellular Vesicles
por: Kannan, Anbarasu, et al.
Publicado: (2020)

Immune Checkpoint Inhibitors in Triple Negative Breast Cancer Treatment: Promising Future Prospects
por: Thomas, Remy, et al.
Publicado: (2021)

Discovery and characterization of an immunogenic neoantigen in a patient with metastatic triple negative breast cancer
por: Assadipour, Yasmine, et al.
Publicado: (2015)

Accuracy of MRI for prediction of response to neo-adjuvant chemotherapy in triple negative breast cancer
por: Bansal, GJ, et al.
Publicado: (2015)

PRAME promotes epithelial-to-mesenchymal transition in triple negative breast cancer
por: Al-Khadairi, Ghaneya, et al.
Publicado: (2019)

NY-ESO-1 Based Immunotherapy of Cancer: Current Perspectives
por: Thomas, Remy, et al.
Publicado: (2018)

Correction: NY-ESO-1 Cancer Testis Antigen Demonstrates High Immunogenicity in Triple Negative Breast Cancer
por: Ademuyiwa, Foluso O., et al.
Publicado: (2012)

Lactate Metabolism and Immune Modulation in Breast Cancer: A Focused Review on Triple Negative Breast Tumors
por: Naik, Adviti, et al.
Publicado: (2020)

Immunotherapy for Triple-Negative Breast Cancer
por: Cao, Yifeng, et al.
Publicado: (2021)

Integrating GWAS with gene expression data to dissect the genetic architecture of triple-negative breast cancer
por: Hicks, Chindo, et al.
Publicado: (2011)

An integrative genomics approach for mapping the emerging genetic susceptibility landscape of triple-negative breast cancer
por: Hicks, Chindo, et al.
Publicado: (2012)

Toward the identification of genetic determinants of breast cancer immune responsiveness
por: Simeone, Ines, et al.
Publicado: (2015)

Expression of MAGE‐A and NY‐ESO‐1 cancer/testis antigens is enriched in triple‐negative invasive breast cancers
por: Raghavendra, Ashwini, et al.
Publicado: (2018)

BCL2 is a predictive marker of adjuvant CMF regimen in triple-negative breast cancer patients
por: Bouchalova, K, et al.
Publicado: (2011)

Transient expression of the cancer/testis cancer antigen NY-ESO-1 in Nicotiana benthamiana using a PVX-based viral vector
por: Lacorte, Cristiano, et al.
Publicado: (2014)

In vivo pulmonary metastatic profile of breast cancer cell lines expressing hormonal receptors versus triple negative
por: Carvalho, M João, et al.
Publicado: (2010)

TEM8 specific T cells target the tumor cells and tumor-associated vasculature in triple negative breast cancer
por: Byrd, Tiara, et al.
Publicado: (2014)

PB.53: Are ethnic minorities more likely to develop triple-negative breast cancer? A systematic review
por: Limbada, R, et al.
Publicado: (2013)

Immunotherapy Treatment for Triple Negative Breast Cancer
por: Berger, Elizabeth R., et al.
Publicado: (2021)

Prospects of Immunotherapy for Triple-Negative Breast Cancer
por: Qiu, Dan, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_5sku1g1el3ao519mak3qj2ojch